Chronic obstructive pulmonary disease and mortality from pneumonia: Meta-analysis

International Journal of Clinical Practice

Volumn 67, Issue 5, 2013, Pages 477-487

  Loke, Y K ^a   Kwok, C S ^b   Wong, J M ^a   Sankaran, P ^a,b   Myint, P K ^a,b  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^b NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID;

ACUTE DISEASE; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EXPOSURE; HUMAN; MORTALITY; PRIORITY JOURNAL; RISK ASSESSMENT;

ADMINISTRATION, INHALATION; ADULT; AGED; COHORT STUDIES; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; MIDDLE AGED; PNEUMONIA; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY SYSTEM AGENTS; RISK FACTORS;

EID: 84876465360     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12120     Document Type: Article

References (32)

1. Torres A, Ewig S,. The strange case of community-acquired pneumonia in COPD. Chest 2011; 139: 483-5.
2. Molinos L, Clemente MG, Miranda B, et al. Community-acquired pneumonia in patients with and without chronic obstructive pulmonary disease. J Infect 2009; 58: 417-24.
3. Neupane B, Walter SD, Krueger P, et al. Predictors of inhospital mortality and re-hospitalization in older adults with community-acquired pneumonia: a prospective cohort study. BMC Geriatr 2010; 10: 22.
4. Snijders D, Van Der Eerden M, De Graaff C, Boersma W,. The influence of COPD on mortality and severity scoring in community-acquired pneumonia. Respiration 2010; 79: 46-53.
5. Myint PK, Lowe D, Stone RA, et al. U.K. National COPD Resources and Outcomes Project 2008: patients with chronic obstructive pulmonary disease exacerbations who present with radiological pneumonia have worse outcome compared to those with non-pneumonic chronic obstructive pulmonary disease exacerbations. Respiration 2011; 82: 320-7.
6. Malo de Molina R, Mortensen EM, Restrepo MI, et al. Inhaled corticosteroid use is associated with lower mortality for subjects with COPD and hospitalised with pneumonia. Eur Respir J 2010; 36: 751-7.
7. Singanayagam A, Chalmers JD, Akram AR, Hill AT,. Impact of inhaled corticosteroid use on outcome in COPD patients admitted with pneumonia. Eur Respir J 2011; 38: 36-41.
8. Davies HT, Crombie IK, Tavakoli M,. When can odds ratios mislead?. BMJ 1998; 316: 989-91. (Pubitemid 28135151)
9. Higgins JPT, Deeks JJ, Altman DG,. Chapter 9: Analysing data and undertaking meta-analyses. In:, Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. Chichester, UK: John Wiley & Sons, 2008: 243-96.
10. Ioannidis JP, Trikalinos TA,. The appropriateness of asymmetry tests for publication bias in meta-analyses: a large survey. CMAJ 2007; 176: 1091-6. (Pubitemid 46649731)
11. Djuric M, Povazan D, Secen N, Perin B,. Frequency and relevance of concomitant diseases in elderly patients hospitalized for community acquired pneumonia [Serbian]. Srp Arh Celok Lek 2009; 137: 619-26.
12. Ewig S, Birkner N, Strauss R, et al. New perspectives on community-acquired pneumonia in 388 406 patients. Results from a nationwide mandatory performance measurement programme in healthcare quality. Thorax 2009; 64: 1062-9.
13. Fujiki R, Kawayama T, Ueyama T, et al. The risk factors for mortality of community-acquired pneumonia in Japan. J Infect Chemother 2007; 13: 157-65. (Pubitemid 47012499)
14. Liapikou A, Polverino E, Ewig S, et al. Severity and outcomes of hospitalised community-acquired pneumonia in COPD patients. Eur Respir J 2012; 39: 855-61.
15. Lim WS, Lewis S, Macfarlane JT,. Severity prediction rules in community acquired pneumonia: a validation study. Thorax 2000; 55: 219-23. (Pubitemid 30245972)
16. Menendez R, Martinez R, Reyes S, et al. Biomarkers improve mortality prediction by prognostic scales in community-acquired pneumonia. Thorax 2009; 64: 587-91.
17. Pifarre R, Falguera M, Vicente-de-Vera C, Nogues A,. Characteristics of community-acquired pneumonia in patients with chronic obstructive pulmonary disease. Respir Med 2007; 101: 2139-44. (Pubitemid 47324242)
18. Rello J, Rodriguez A, Torres A, et al. Implications of COPD in patients admitted to the intensive care unit by community-acquired pneumonia. Eur Respir J 2006; 27: 1210-6. (Pubitemid 44914306)
19. Restrepo MI, Mortensen EM, Pugh JA, Anzueto A,. COPD is associated with increased mortality in patients with community-acquired pneumonia. Eur Respir J 2006; 28: 346-51. (Pubitemid 44914234)
20. Ruiz de Ona JM, Gomez Fernandez M, Celdran J, Puente-Maestu L,. Pneumonia in the patient with chronic obstructive pulmonary disease. Levels of severity and risk classification. [Spanish]. Arch Bronconeumol 2003; 39: 101-5. (Pubitemid 36505552)
21. Gungor G, Yazicioglu Mocin O, Acarturk E, et al. The influence of community-acquired pneumonia to the clinical course in COPD cases admitted to intensive care unit with acute respiratory failure. [Turkish]. Tuberkuloz ve Toraks 2010; 58: 408-17.
22. Jeong SW, Lee JH, Choi KJ, et al. Comparisons of clinical characteristics and outcomes in COPD patients hospitalized with community-acquired pneumonia and acute exacerbation. [Korean]. Tubercu Respir Dis 2010; 69: 31-8.
23. Lieberman D, Gelfer Y, Varshavsky R, et al. Pneumonic vs nonpneumonic acute exacerbations of COPD. Chest 2002; 122: 1264-70. (Pubitemid 35339539)
24. Steer J, Gibson J, Bourke SC,. The DECAF Score: predicting hospital mortality in exacerbations of chronic obstructive pulmonary disease. Thorax 2012; 67: 970-6.
25. Chen D, Restrepo MI, Fine MJ, et al. Observational study of inhaled corticosteroids on outcomes for COPD patients with pneumonia. Am J Respir Crit Care Med 2011; 184: 312-6.
26. Ernst P, Gonzalez AV, Brassard P, Suissa S,. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med 2007; 176: 162-6. (Pubitemid 47057852)
27. Joo MJ, Au DH, Fitzgibbon ML, Lee TA,. Inhaled corticosteroids and risk of pneumonia in newly diagnosed COPD. Respir Med 2010; 104: 246-52.
28. Singh S, Amin AV, Loke YK,. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch Intern Med 2009; 169: 219-29.
29. Holguin F, Folch E, Redd SC, Mannino DM,. Comorbidity and mortality in COPD-related hospitalizations in the United States, 1979 to 2001. Chest 2005; 128: 2005-11. (Pubitemid 41507534)
30. Raguso CA, Luthy C,. Nutritional status in chronic obstructive pulmonary disease: role of hypoxia. Nutrition 2011; 27: 138-43.
31. Alfageme I, Vazquez R, Reyes N, et al. Clinical efficacy of anti-pneumococcal vaccination in patients with COPD. Thorax 2006; 61: 189-95.
32. Furumoto A, Ohkusa Y, Chen M, et al. Additive effect of pneumococcal vaccine and influenza vaccine on acute exacerbation in patients with chronic lung disease. Vaccine 2008; 26: 4284-9.